{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:15:40Z","timestamp":1783606540575,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C431"],"award-info":[{"award-number":["C431"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019209","name":"Roche Innovation Center Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse, highlighting the need to understand the mechanisms behind treatment failure to improve patient care. Resistance to chemotherapy is often caused by the ability of malignant B-cells to migrate to the bone marrow and home into the stromal layer. Therefore, this study aimed to investigate whether stromal cells were also able to inhibit type II anti-CD20 antibody mechanisms of action, contributing to resistance to therapy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A stromal-tumor co-culture was established <jats:italic>in vitro<\/jats:italic> between Raji or Daudi B-cell tumor cells and M210B4 stromal cells in 24 well plates.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Contact with stromal cells was able to protect tumor cells from obinutuzumab mediated programmed cell death (PCD), antibody dependent cellular phagocytosis and antibody dependent cellular cytotoxicity. Furthermore, such protection required direct contact between stroma and tumor cells. Stromal cells appeared to interfere with obinutuzumab mediated B-cell homotypic adhesion through inhibiting and reversing actin remodelling, potentially as a result of stromal-tumor cell contact leading to downregulation of CD20 on the surface of tumor cells. Further evidence for the potential role of CD20 downregulation comes through the reduction in surface CD20 expression and inhibition of obinutuzumab mediated PCD when tumor cells are treated with Ibrutinib in the presence of stromal cells. The proteomic analysis of tumor cells after contact with stromal cells led to the identification of a number of altered pathways including those involved in cell adhesion and the actin cytoskeleton and remodeling.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> This work demonstrates that contact between tumor cells and stromal cells leads to inhibition of Obinutuzumab effector functions and has important implications for future therapies to improve outcomes to anti-CD20 antibodies. A deeper understanding of how anti-CD20 antibodies interact with stromal cells could prove a useful tool to define better strategies to target the micro-environment and ultimately improve patient outcomes in B-cell malignancies.<\/jats:p>","DOI":"10.3389\/fcell.2023.1270398","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:41:05Z","timestamp":1698763265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies"],"prefix":"10.3389","volume":"11","author":[{"given":"Ester","family":"Fagnano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Pendharkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madyson","family":"Colton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Crespi","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Klymenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrejs","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Honeychurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor J.","family":"Cheadle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-12-3015","article-title":"Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140","volume":"19","author":"Beider","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/leu.2014.12","article-title":"B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies","volume":"28","author":"Bojarczuk","year":"2014","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2141.2010.08316.x","article-title":"The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies","volume":"151","author":"Buchner","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1189\/jlb.71.3.495","article-title":"Engagement of \u03b14\u03b21 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine","volume":"71","author":"de la Fuente","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4161\/19420862.2015.989020","article-title":"Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies","volume":"7","author":"Duong","year":"2015","journal-title":"MAbs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.leukres.2008.03.003","article-title":"Bone marrow fibroblasts induce expression of PI3K\/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells","volume":"32","author":"Edelmann","year":"2008","journal-title":"Leuk. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1301249","article-title":"Glycoengineering of therapeutic antibodies enhances monocyte\/macrophage-mediated phagocytosis and cytotoxicity","volume":"192","author":"Herter","year":"2014","journal-title":"J. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","article-title":"Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway","volume":"119","author":"Honeychurch","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3109\/10428194.2011.601698","article-title":"Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists","volume":"53","author":"Hu","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1172\/JCI37884","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1523-1747.1999.00479.x","article-title":"N-cadherin expressed on malignant T cell lymphoma cells is functional, and promotes heterotypic adhesion between the lymphoma cells and mesenchymal cells expressing N-cadherin","volume":"112","author":"Kawamura-Kodama","year":"1999","journal-title":"J. Invest. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2006.11.024","article-title":"Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an \"angiogenic switch","volume":"31","author":"Kay","year":"2007","journal-title":"Leuk. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1182\/blood.v91.7.2387","article-title":"Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells","volume":"91","author":"Lagneaux","year":"1998","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/sj.leu.2404723","article-title":"Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB\/p52) in non-Hodgkin's lymphoma cells","volume":"21","author":"Lwin","year":"2007","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood.v83.3.758.758","article-title":"Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells","volume":"83","author":"Manabe","year":"1994","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/bjh.13286","article-title":"Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL","volume":"169","author":"Marquez","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2002-04-1032","article-title":"Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy","volume":"101","author":"Meunier","year":"2003","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","article-title":"Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin \u03b1-4-\u03b2-1 (VLA-4) with natalizumab can overcome this resistance","volume":"155","author":"Mraz","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B31","unstructured":"Cancer statistics"},{"key":"B32","unstructured":"Non-Hodgkin lymphoma \u2014 cancer stat facts"},{"key":"B33","unstructured":"Using the immune system in the fight against cancer: discovery of rituximab2012"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2141.1996.00305.x","article-title":"Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro","volume":"92","author":"Panayiotidis","year":"1996","journal-title":"Br. J. Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","article-title":"Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis","volume":"128","author":"Pavlasova","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ijc.2910390121","article-title":"EL-4 metastases in spleen and bone marrow suppress the NK activity generated in these organs","volume":"39","author":"Sarzotti","year":"1987","journal-title":"Int. J. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.exphem.2019.10.004","article-title":"Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies","volume":"79","author":"Scialdone","year":"2019","journal-title":"Exp. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2009-03-206482","article-title":"Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells","volume":"114","author":"Sharma","year":"2009","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/cas.12392","article-title":"Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis","volume":"105","author":"Takata","year":"2014","journal-title":"Cancer Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","article-title":"Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies","volume":"125","author":"Tipton","year":"2015","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3960\/jslrt.56.89","article-title":"Genetic and epigenetic modulation of CD20 expression in B-cell malignancies: molecular mechanisms and significance to rituximab resistance","volume":"56","author":"Tomita","year":"2016","journal-title":"J. Clin. Exp. Hematop"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1270398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:41:09Z","timestamp":1698763269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1270398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":43,"alternative-id":["10.3389\/fcell.2023.1270398"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1270398","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"article-number":"1270398"}}